2024-05-31 06:49:06 ET
More on Sanofi, Regeneron, etc.
- Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)
- Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks
- Regeneron Pharmaceuticals, Inc. (REGN) Q1 2024 Earnings Call Transcript
- Sanofi's Sarclisa gets accepted for FDA priority review for treatment of multiple myeloma
- Sanofi says asthma candidate rilzabrutinib buoyed by phase 2 results
Read the full article on Seeking Alpha
For further details see:
Regeneron/ Sanofi say FDA has delayed Dupixent COPD label